Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes

Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience ... L'articolo Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes è un contenuto originale di 01net.

Insulet shares outcomes from fully closed-loop insulin pump study

The Omnipod 5 worn on the arm. [Image courtesy of Insulet]Insulet (Nasdaq:PODD) today shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes. The maker of the Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — said during a 2025 Investor Day event that it plans to bring its first fully closed-loop system to the type 2 diabetes population by 2…